Orelabrutinib in Combination With R2 Regimen for R/R CD20+ B-cell Lymphoma
Status:
Not yet recruiting
Trial end date:
2023-09-30
Target enrollment:
Participant gender:
Summary
Obrutinib is a highly selective BTKi and has shown efficacy in CLL/MCL. This study aims to
investigate the initial efficacy and safety of obrutinib combined with R2 regimen in the
treatment of relapsed or refractory CD20+B cell lymphoma